Elasmogen is developing site-specific and sight-saving therapies for inflammatory eye disease and in particular for those patients that fail to respond to current small molecule and monoclonal antibody therapies. We are always keen to speak to companies that may have new drug delivery formats (eye, skin, gut, lung) that may benefit from the remarkable properties of our soloMER domains.
In addition, we have already shown that our soloMERs can be adapted for systemic therapy where the capability to bind cryptic and neutralising epitopes (and bi/tri specificity) can be combined with half-life extension and immune system recruitment to deliver the same therapeutic potency as monoclonal antibodies but from a protein of between 35 – 90 kDA.
Elasmogen would be open to discussing access and partnerships to our auto-immune mediated anti-inflammatory programmes for systemic treatments of disease.
The pharmacokinetic properties of soloMERs offer many advantages over existing antibody formats and therefore opportunities for their exploitation to soloMER conjugates in oncology is an area of interest for future collaboration and partnerships. Existing partnerships include: Almac Discovery Ltd.
Combining Elasmogen’s soloMER™ technology and the unique capabilities of Feldan’s Shuttle platform will be used to develop a delivery system and binding domains to intracellular targets as a specific and safer alternative to small molecule therapeutics. This is an area of particular interest for future collaboration and partnerships. Existing partnerships include: Amgen Inc (two undisclosed targets).
To discuss partnering and licensing opportunities that will enable access to our soloMER™ generation and NDure™ half-life extension platforms or to our products in auto-immune mediated inflammation please contact email@example.com.